Celgene Corporation Securities Litigation Settlement
This settlement is closed to new claims — the deadline was April 13, 2026. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →
What happened
Investors alleged that Celgene Corporation and officers Terrie Curran and Philippe Martin violated federal securities laws by making false and misleading statements regarding certain Celgene products and drug candidates, including GED-0301, Otezla, and Ozanimod. The defendants have agreed to settle the claims for $239 million without admitting wrongdoing.
Do you qualify?
All persons and entities who purchased Celgene common stock between April 27, 2017 and April 27, 2018 and were damaged thereby. Excluded are defendants, company directors and officers during the class period, company subsidiaries and affiliates, and certain family members.
How to file
Submit a Claim Form with required supporting documentation postmarked or submitted online no later than April 13, 2026. The Claim Form is available on the File a Claim page of the settlement website in English and Spanish.
Common questions
- How much does the Celgene Corporation Securities Litigation Settlement pay?
- The total settlement fund is $239M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
- What is the claim deadline for the Celgene Corporation Securities Litigation Settlement?
- This settlement is closed to new claims — the deadline was April 13, 2026. Once a claim deadline passes you generally forfeit your share, even if you qualified.
- Do I need proof of purchase for the Celgene Corporation Securities Litigation Settlement?
- Yes. This settlement asks for documentation supporting your claim — a receipt, an account record, or the notice you were sent. Check the official settlement website for exactly which documents are accepted.
- Is the Celgene Corporation Securities Litigation Settlement notice real, or a scam?
- JND Legal Administration is the settlement administrator for this case. Claims are filed at celgenesecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
- When will payments from the Celgene Corporation Securities Litigation Settlement be sent?
- Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. The final approval hearing for this case is set for May 4, 2026; no payments can be issued before a settlement receives final approval.
New to class actions?
This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.
More securities settlements
View all →Revance Securities Settlement
Revance Therapeutics and its executives made material misrepresentations and omissions regarding the company's relationship with Teoxane SA and the tender offer and merger transaction with Crown Laboratories, Inc., allegedly violating federal securities laws. Defendants deny any wrongdoing or liability.
Not yet determinable; depends on number of valid claims submitted
Biogen Securities Litigation Settlement
Biogen Inc. investors have settled a securities litigation case for $18.9 million in cash. The settlement resolves claims related to purchases of Biogen common stock during the specified class period.
NJ Bureau of Securities Settlement with Credit Suisse
Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.
Stitch Fix Securities Litigation Settlement
Stitch Fix, Inc. is settling a securities class action lawsuit without admitting wrongdoing. The Lead Plaintiffs alleged that Stitch Fix issued misleading statements about its business, and shareholders who purchased the stock during the class period suffered damages as a result.